“We didn’t want to be “just the next event,” so we focused on creating a spirit of connection and openness where it’s highly likely you’ll meet someone or hear something that just might change everything.”
Montreal, Quebec (PRWEB) January 30, 2013
Scimega, (http://www.scimega.com) the experts in early phase clinical oncology site start-up and patient recruitment, today announced that, as a follow-up to last year’s highly popular Optimizing Oncology Clinical Trials Workshop, it will be hosting a breakfast symposium for senior clinical research executives on February 22nd from 8:00am – 10:30am at The Hotel Rex in San Francisco.
Special guest, Dr. David M. Dilts, Director of Strategy Alignment for the Knight Cancer Institute and co-director of the Center for Management Research in Healthcare at the Oregon Health & Science University, will share his views on what must be done to prevent the clinical trial industry in North America from going the way of the Oldsmobile.
“At most industry events, you can predict exactly what’s going to be said,” commented Roberto Lara, Director of Business Development for Scimega. “People tend to be very guarded and protective – like a party where no one is drinking,” he continued. “We didn’t want to be “just the next event,” so we focused on creating a spirit of connection and openness where it’s highly likely you’ll meet someone or hear something that just might change everything.”
Attendees will walk away with some great insight on how they can accelerate their oncology site start-up times by 50%. They'll also learn why Canada is ideally suited for early phase oncology trials, and find out what they need to be eligible for a 30% rebate on their professional service fees.
To register for the February 22nd, 8am Breakfast Symposium, Accelerating Oncology Site Start-Up by 50%, please go to: http://scimega.com/land-bayareasymposium.php
Scimega Research Inc. is a Canadian-based oncology clinical research organization (CRO) focused on connecting sponsors, investigators and patients in the biopharmaceutical research industry. We play a vital role in improving site selection, speeding up study start-up and patient recruitment, while delivering pertinent, high quality data.
Our value lies in our privileged relationships with a pre-qualified network of highly motivated and internationally renowned investigators, who are at the forefront of oncology clinical research. Our clients benefit from our in-depth oncology expertise and from an immediate, accurate assessment of their protocols.
If you would like more information on our services or to schedule an interview with a Scimega executive, please contact Roberto Lara at 450-629-2200 ext.226 or email him at firstname.lastname@example.org.